


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	1	of	1	Application Number	10/712,332
				Filing Date	November 13, 2003
				First Named Inventor	David L. Wolf et al.
				Group Art Unit	1648
				Examiner Name	N/A
				Attorney Docket Number	MPI90-002CP2DV1CNBCN3M

[illegible][illegible]

Examiner Signature		Date Considered	11/15/05
-----------------------	---	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/712,332
		Filing Date	November 13, 2003
		First Named Inventor	David L. Wolf
		Group Art Unit	1648
		Examiner Name	N/A
Sheet	1	of	4
		Attorney Docket Number	MPI90-002CP2DV1CNBCN3M

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	B1	Hoover, R.L. et al., "The Adhesive Interaction between Polymorphonuclear Leukocytes and Endothelial Cells in vitro" <u>Cell</u> , (June, 1978) Vol. 14, No. 2 pp. 423-428.	
	B2	Etingin, O.R. et al., "Viral Activation of the Coagulation Cascade: Molecular Interactions at the Surface of Infected Endothelial Cells" <u>Cell</u> , (May 18, 1990) Vol. 61, No. 4 pp. 657-662.	
	B3	Furie, B. et al., "The Molecular Basis of Blood Coagulation" <u>Cell</u> , (May 20, 1988) Vol. 53, No. 4 pp. 505-518	
	B4	Di Scipio, R.G. et al., "Activation of Human Factor X (Stuart Factor) by a Protease from Russell's Viper Venom" <u>Biochemistry</u> , (November 29, 1977) Vol. 15, No. 24 pp. 5253-5260.	
	B5	Nesheim, M.E. et al., "The Contribution of bovine Factor V and Factor Va to the Activity of Prothrombinase" <u>The Journal of Biological Chemistry</u> , (November 10, 1979) Vol. 254, No. 21 pp. 10952-10962.	
	B6	Nasheim, M.E. et al., "Cofactor Dependence of Factor Xa Incorporation into the Prothrombinase Complex" <u>The Journal of biological Chemistry</u> , (July 10, 1981) Vol. 256, No. 13 pp. 6537-6540.	
	B7	Skogen, W.F. et al., "Comparison of Coagulation Factor Xa and Des-(1-44) factor Xa in the Assembly of Prothrombinase" <u>The Journal of Biological Chemistry</u> , (February 25, 1984) Vol. 259, No. 4 pp. 2306-2310.	
	B8	Krishnaswamy, S. et al., "Prothrombinase Complex Assembly" <u>The Journal of Biological Chemistry</u> , (March 15, 1988) Vol. 263, No. 8 pp. 3823-3824.	

Examiner Signature		Date Considered	11/15/05
---------------------------	--	------------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;"><i>(use as many sheets as necessary)</i></p>				Complete if Known	
		Application Number	10/712332		
		Filing Date	November 13, 2003		
		First Named Inventor	Wolf, David L.		
		Group Art Unit			
		Examiner Name			
Sheet	2	of	4	Attorney Docket Number	MPI90-002CP2DV1CNBCN3M

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B9	Hutsen, E.J. et al., "The Active Site of Blood Coagulation Factor Xa" <u>The Journal of Biological Chemistry</u> , (September 25, 1987) Vol. 262, No. 27 pp. 12953-12961.	
	B10	Girard, T.J. et al., "Functional Significance of the Kunitz-type Inhibitory Domains of Lipoprotein-associated Coagulation Inhibitor" <u>Nature</u> , (April 6, 1989) Vol. 338, pp. 518-520	
	B11	Girard, T.J. et al., "Inhibition of Factor VIIa-tissue Factor Coagulation Activity by a Hybrid Protein" (June 15, 1990) Vol. 248, No. 4961 pp. 1421-1424.	
	B12	Dunwiddie, C. et al., "Antistasin, A Leech-derived Inhibitor of Factor Xa. Kinetic Analysis of Enzyme Inhibition and Identification of the Reactive Site" <u>The Journal of Biological Chemistry</u> , (October 5, 1989) Vol. 264, No. 28 pp. 16694-16699.	
	B13	Waxman, L. et al., "Tick Anticoagulant Peptide (TAP) is a Novel Inhibitor of Blood Coagulation Factor Xa" <u>The Journal of Biological Chemistry</u> , (May 4, 1990) Vol. 248, No. 4955 pp. 593-596.	
	B14	Bajaj, S.P. et al., "Simultaneous Purification of Bovine Prothrombin and Factor X" <u>The Journal of Biological Chemistry</u> , (November 25, 1973) Vol. 248, No. 22 pp. 7729-7741.	
	B15	Kaul, R.K. et al., "Isolation and Characterization of Human Blood-Coagulation Factor X cDNA" <u>Gene</u> , (1986) Vol. 41, Nos. 2-3 pp. 311-314.	
	B16	Bernardi, F., et al., "Partial Gene Deletion in a Family with Factor X Deficiency" <u>Blood</u> , (June 1, 1989) Vol. 73, No. 8 pp. 2123-2127.	

Examiner Signature		Date Considered	1/15/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/712332
		Filing Date	November 13, 2003
		First Named Inventor	Wolf, David L.
		Group Art Unit	
		Examiner Name	
Sheet	3	of	4
		Attorney Docket Number	MPI90-002CP2DV1CNBCN3M

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	B17	Cassels, R. et al., "The Interaction of Streptokinase-Plasminogen Activator Complex, Tissue-Type Plasminogen Activator, Urokinase and Their Acylated Derivatives with Fibrin and Cyanogen Bromide Digest of Fibrinogen. Relationship to Fibrinolytic Potency in vitro" <u>The Journal of Biological Chemistry</u> , (October 15, 1987) Vol. 247, No. 2 pp. 395-400.	
	B18	Crabbe, S.J. et al., "Acylated Plasminogen-Streptokinase Activator Complex: A New Approach to Thrombolytic Therapy" <u>Pharmacotherapy</u> , (1990) Vol. 10, No. 2 pp. 115-126.	
	B19	Fair, D.S. et al., "Isolation and Characterization of the Factor X Friuli Variant" <u>Blood</u> , (June 1, 1989) Vol. 73, No. 8 pp. 2108-2116.	
	B20	Hassan, H.J. et al., "Multiple Polymorphic Sites in Factor X Locus" <u>Blood</u> , (May 1, 1988) Vol. 71, no. 5 pp. 1353-1356.	
	B21	Reddy, S.V. et al., "Molecular Characterization of Human Factor XSan Antonio" <u>Blood</u> , (October 1, 1989) Vol. 74, No. 5 pp. 1486-1490.	
	B22	Stürzebecher, J. et al., "Stable Acyl-Derivatives of Tissue-Type Plasminogen Activator" <u>Thrombosis Research</u> , (September 15, 1987) Vol. 47, No. 6 pp. 699-703.	
	B23	Watzke, H.H. et al., "Molecular Defect (Glu ¹¹⁴ →Lys) and Its Functional Consequences in a Hereditary Factor X Deficiency (Factor X "Vorarlberg")" <u>The Journal of Biological Chemistry</u> , (July 15, 1990) Vol. 265, No. 20 pp. 11982-11989.	
	B24	Neuenschwander, P. et al., "The Use of Acetylated Factor X to Prevent Feedback Activation of Factor VIII During Factor X Activation: A Tool for Kinetic Studies" <u>Analytical Biochemistry</u> , (February 1, 1990) Vol. 184, No. 2 pp. 347-352.	

Examiner Signature		Date Considered	1/15/05
---------------------------	--	------------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/712332
		Filing Date	November 13, 2003
		First Named Inventor	Wolf, David L.
		Group Art Unit	
		Examiner Name	
Sheet 4 of 4	Attorney Docket Number	MPI90-002CP2DV1CNBCN3M	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	B25	Fung, M.R. et al., "Characterization of an almost Full-length cDNA Coding for Human Blood Coagulation Factor X" <u>Proceedings of the National Academy of Sciences of the United States of America</u> , (June 1985) Vol. 82, No. 11 pp. 3591-3595.	
	B26	Davie, E.W., "The Blood Coagulation Factors: Their cDNAs, Genes, and Expression" <u>Haemostasis and Thrombosis</u> , Second Edition, R.W. Colman et al., eds., (1987) J.B. Lippencott, Philadelphia, PA, Chapter 16, pp. 242-267.	
	B27	Steinberg, et al., "Activation of Factor X" <u>Haemostasis and Thrombosis</u> , Second Edition, R.W. Colman et al., eds., (1987) J.B. Lippencott, Philadelphia, PA, Chapter 7, pp. 112-119.	
	B28	Colman, et al., <u>Haemostasis and Thrombosis</u> , Second Edition, R.W. Colman et al., eds., (1987) J.B. Lippencott, Philadelphia, PA, Chapter 1, pp. 3-17.	
	B29	Fears, "Development of Anisoylated Plasminogen-Streptokinase Activator Complex from the Acyl Enzyme Concept" <u>Seminars in Thrombosis and Hemostasis</u> , (1989), Vol. 15, No. 2 pp. 129-139.	
	B29	Fears, "The Protective Effect of Acylation on the Stability of Anisoylated Plasminogen Streptokinase Activator Complex in Human Plasma" <u>Drugs 33 Supplemental 3</u> , (1987) pp. 57-63.	
	B30	Levine, "Clinical Manifestations and Therapy of Hemophilias A and B" <u>Plasma Coagulation Factors</u> , pp. 97-111.	
	B31	Nucci, M.L. et al., "the Therapeutic Value of Poly(ethylene Glycol)-Modified Proteins" <u>Advanced Drug Delivery Reviews</u> , (1991) Vol. 6, pp. 133-151.	

Examiner Signature		Date Considered	1/15/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.